Author: Fang, Jie; Li, Hui; Du, Wei; Yu, Ping; Guan, Ying-Yun; Ma, Shi-Yu; Liu, Dong; Chen, Wei; Shi, Guo-Chao; Bian, Xiao-Lan
Title: Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study Cord-id: t33nw4zb Document date: 2020_9_18
ID: t33nw4zb
Snippet: OBJECTIVE: Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan City, China, coronavirus disease 2019 (COVID-19) has become a global pandemic. However, no special therapeutic drugs have been identified for COVID-19. The aim of this study was to search for drugs to effectively treat COVID-19. MATERIALS AND METHODS: We conducted a retrospective cohort study with a total of 162 adult inpatients (≥18 years old) from Ruijin Hospital (Shanghai, China) and Tongj
Document: OBJECTIVE: Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan City, China, coronavirus disease 2019 (COVID-19) has become a global pandemic. However, no special therapeutic drugs have been identified for COVID-19. The aim of this study was to search for drugs to effectively treat COVID-19. MATERIALS AND METHODS: We conducted a retrospective cohort study with a total of 162 adult inpatients (≥18 years old) from Ruijin Hospital (Shanghai, China) and Tongji Hospital (Wuhan, China) between January 27, 2020, and March 10, 2020. The enrolled COVID-19 patients were first divided into the Lianhuaqingwen (LHQW) monotherapy group and the LHQW + Arbidol combination therapy group. Then, these two groups were further classified into moderate and severe groups according to the clinical classification of COVID-19. RESULTS: The early combined usage of LHQW and Arbidol can significantly accelerate the recovery of patients with moderate COVID-19 by reducing the time to conversion to nucleic acid negativity, the time to chest CT improvement, and the length of hospital stay. However, no benefit was observed in severe COVID-19 patients treated with the combination of LHQW + Arbidol. In this study, both Arbidol and LHQW were well tolerated without serious drug-associated adverse events. CONCLUSION: The early combined usage of LHQW and Arbidol may accelerate recovery and improve the prognosis of patients with moderate COVID-19.
Search related documents:
Co phrase search for related documents- acid conversion and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acid conversion and lopinavir ritonavir group: 1, 2
- acid conversion and lung involvement: 1
- acid negativity and lopinavir ritonavir: 1
- active trial and acute exacerbation: 1
- acute exacerbation and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute exacerbation and lung tissue bronchoalveolar lavage fluid: 1
- acute respiratory distress syndrome and adenovirus type: 1, 2, 3, 4, 5
- acute respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64
- acute respiratory distress syndrome and lopinavir ritonavir group: 1
- acute respiratory distress syndrome and lung attenuation: 1, 2
- acute respiratory distress syndrome and lung involvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48
- acute respiratory distress syndrome and lung involvement extent: 1, 2, 3, 4, 5
- acute respiratory distress syndrome and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute respiratory distress syndrome and lung tissue bronchoalveolar lavage fluid: 1, 2
- acute respiratory distress syndrome development and lung involvement: 1, 2
- acute respiratory distress syndrome development and lung tissue: 1, 2
- adenovirus type and lung tissue: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date